Your browser doesn't support javascript.
loading
Pathogenic SCN2A variants cause early-stage dysfunction in patient-derived neurons.
Asadollahi, R; Delvendahl, I; Muff, R; Tan, G; Rodríguez, D G; Turan, S; Russo, M; Oneda, B; Joset, P; Boonsawat, P; Masood, R; Mocera, M; Ivanovski, I; Baumer, A; Bachmann-Gagescu, R; Schlapbach, R; Rehrauer, H; Steindl, K; Begemann, A; Reis, A; Winkler, J; Winner, B; Müller, M; Rauch, A.
Afiliación
  • Asadollahi R; Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
  • Delvendahl I; Faculty of Engineering and Science, University of Greenwich London, Medway Campus, Chatham Maritime ME4 4TB, UK.
  • Muff R; Department of Molecular Life Sciences, University of Zurich, Zurich 8057, Switzerland.
  • Tan G; Neuroscience Center Zurich, University of Zurich, Zurich 8057, Switzerland.
  • Rodríguez DG; Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
  • Turan S; Functional Genomics Center Zurich, ETH Zurich and University of Zurich, Zurich 8057, Switzerland.
  • Russo M; Functional Genomics Center Zurich, ETH Zurich and University of Zurich, Zurich 8057, Switzerland.
  • Oneda B; Department of Stem Cell Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen 91054, Germany.
  • Joset P; Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
  • Boonsawat P; Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
  • Masood R; Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
  • Mocera M; Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
  • Ivanovski I; Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
  • Baumer A; Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
  • Bachmann-Gagescu R; Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
  • Schlapbach R; Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
  • Rehrauer H; Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
  • Steindl K; Functional Genomics Center Zurich, ETH Zurich and University of Zurich, Zurich 8057, Switzerland.
  • Begemann A; Functional Genomics Center Zurich, ETH Zurich and University of Zurich, Zurich 8057, Switzerland.
  • Reis A; Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
  • Winkler J; Institute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
  • Winner B; Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen 91054, Germany.
  • Müller M; Department of Molecular Neurology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen 91054, Germany.
  • Rauch A; Center for Rare Diseases Erlangen, University Hospital Erlangen, Erlangen 91054, Germany.
Hum Mol Genet ; 32(13): 2192-2204, 2023 06 19.
Article en En | MEDLINE | ID: mdl-37010102
ABSTRACT
Pathogenic heterozygous variants in SCN2A, which encodes the neuronal sodium channel NaV1.2, cause different types of epilepsy or intellectual disability (ID)/autism without seizures. Previous studies using mouse models or heterologous systems suggest that NaV1.2 channel gain-of-function typically causes epilepsy, whereas loss-of-function leads to ID/autism. How altered channel biophysics translate into patient neurons remains unknown. Here, we investigated iPSC-derived early-stage cortical neurons from ID patients harboring diverse pathogenic SCN2A variants [p.(Leu611Valfs*35); p.(Arg937Cys); p.(Trp1716*)] and compared them with neurons from an epileptic encephalopathy (EE) patient [p.(Glu1803Gly)] and controls. ID neurons consistently expressed lower NaV1.2 protein levels. In neurons with the frameshift variant, NaV1.2 mRNA and protein levels were reduced by ~ 50%, suggesting nonsense-mediated decay and haploinsufficiency. In other ID neurons, only protein levels were reduced implying NaV1.2 instability. Electrophysiological analysis revealed decreased sodium current density and impaired action potential (AP) firing in ID neurons, consistent with reduced NaV1.2 levels. In contrast, epilepsy neurons displayed no change in NaV1.2 levels or sodium current density, but impaired sodium channel inactivation. Single-cell transcriptomics identified dysregulation of distinct molecular pathways including inhibition of oxidative phosphorylation in neurons with SCN2A haploinsufficiency and activation of calcium signaling and neurotransmission in epilepsy neurons. Together, our patient iPSC-derived neurons reveal characteristic sodium channel dysfunction consistent with biophysical changes previously observed in heterologous systems. Additionally, our model links the channel dysfunction in ID to reduced NaV1.2 levels and uncovers impaired AP firing in early-stage neurons. The altered molecular pathways may reflect a homeostatic response to NaV1.2 dysfunction and can guide further investigations.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Epilepsia / Discapacidad Intelectual Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Hum Mol Genet Asunto de la revista: BIOLOGIA MOLECULAR / GENETICA MEDICA Año: 2023 Tipo del documento: Article País de afiliación: Suiza

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Epilepsia / Discapacidad Intelectual Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Hum Mol Genet Asunto de la revista: BIOLOGIA MOLECULAR / GENETICA MEDICA Año: 2023 Tipo del documento: Article País de afiliación: Suiza